The Pivotal Role of Interleukin-17 in the Pathogenesis of Systemic Lupus Erythematosus
DOI:
https://doi.org/10.36330/kmj.v21.i1.19080Keywords:
Systemic Lupus Erythematosus;, Interleukin 17;, Cytokines;Abstract
Background: Systemic lupus erythematosus(SLE) is a typical autoimmune illness distinguished by developing many autoantibodies against various cellular components. Interleukin17 (IL-17) is a powerful proinflammatory cytokine that plays an important role in host immunological defense, tissue healing, and the etiology of inflammatory diseases. Purpose: This study aimed to characterize the demographic and clinical profiles of SLE patients and compare IL-17 levels between SLE patients and healthy controls. Methods: 126 participants were enrolled, including SLE patients with ages ranging from 10 to 60 years admitted from Merjan Teaching Hospital and AL-Qassim General Hospital during the period from 1st August 2024 to 31th January 2025. and matched healthy controls. Demographic data and IL-17 levels were collected and analyzed using appropriate non-parametric statistical tests to identify significant differences between groups. The concentrations of IL-17 were assessed using a sandwich (ELISA) assay and a standard curve. Results: Consistent with previous reports, the majority of SLE patients were female (96.8%) and primarily in the 21–40-year age range. While the sex distribution was similar between SLE cases and controls, a significant difference in age distribution was observed (p = 0.027). IL-17 levels (90.30) pg/ml are significantly higher in SLE patients compared to controls (36.70 pg/ml) (p < 0.001), suggesting a foundation for future therapeutic strategies targeting this cytokine. Implications: Further investigations should explore the synergistic effects of IL-17 with other inflammatory cytokines, particularly in lupus nephritis and neuropsychiatric SLE Since the study suggests that IL-17 expression correlates with organ involvement, targeted therapies could be tailored to patients exhibiting IL-17-driven inflammation. Additional materials: the research was approved by the local Department of the Ministry of Health, Babylon Health Directorate committee:1542. Conclusion: Research demonstrates a strong association between IL-17 and lupus nephritis and its contribution to neuropsychiatric manifestations of SLE. IL-17 is a possible biomarker for disease severity, emphasizing its involvement in chronic inflammation mediated by T-helper 17 (Th17) cells. By elucidating the inflammatory pathways driven by IL-17, this study advances the body of scientific knowledge on SLE pathophysiology and provides a foundation for future therapeutic strategies targeting this cytokine
Downloads
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Duaa Sami Segatri, Eman Hasani AL-Salami

This work is licensed under a Creative Commons Attribution 4.0 International License.
which allows users to copy, create extracts, abstracts, and new works from the Article, alter and revise the Article, and make commercial use of the Article (including reuse and/or resale of the Article by commercial entities), provided the user gives appropriate credit (with a link to the formal publication through the relevant DOI), provides a link to the license, indicates if changes were made and the licensor is not represented as endorsing the use made of the work. The authors hold the copyright for their published work on the KMJ website, given that KMJ is responsible to appreciate citation for their work, which is released under CC-BY-4.0 enabling the unrestricted use, distribution, and reproduction of an article in any medium, provided that the original work is properly cited.









